A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
To explore the safety, tolerability, and clinical effects of decitabine combined with
Second-line chemotherapy regimens for patients with relapsed or refractory T-lymphoblastic
lymphoma.